Madrid, Spain

Javier Adrio

This inventor holds 1 USPTO granted patent. Top assignee: Pharma Mar, S.a.. Active years: 2006.


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Javier Adrio in Antitumoral Compounds

Introduction

Javier Adrio is a notable inventor based in Madrid, Spain. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antitumoral compounds. His innovative work focuses on new spisulosine derivatives that have potential applications in treating tumors.

Latest Patents

Javier Adrio holds a patent for antitumoral compounds, specifically new spisulosine derivatives. The patent describes a formula wherein various substituents can be represented, including H, OH, OR', and others. This innovative approach aims to enhance the efficacy of treatments for tumors, showcasing his commitment to advancing medical science.

Career Highlights

Adrio's career is marked by his dedication to research and development in the pharmaceutical industry. He is currently associated with Pharma Mar, S.A., a company known for its focus on marine-derived pharmaceuticals. His work has contributed to the company's reputation as a leader in innovative cancer treatments.

Collaborations

Throughout his career, Javier Adrio has collaborated with esteemed colleagues such as Jose Luis Aceña and Carmen Cuevas. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of pharmaceutical research.

Conclusion

Javier Adrio's contributions to the development of antitumoral compounds highlight his role as an innovative inventor in the pharmaceutical industry. His work continues to pave the way for advancements in cancer treatment, demonstrating the importance of research and collaboration in achieving medical breakthroughs.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…